Docosanol
- Generic Name
- Docosanol
- Brand Names
- Abreva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H46O
- CAS Number
- 661-19-8
- Unique Ingredient Identifier
- 9G1OE216XY
- Background
Docosanol is a drug used for topical treatment for recurrent herpes simplex labialis episodes (episodes of cold sores or fever blisters). A saturated 22-carbon aliphatic alcohol, docosanol exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol inhibits fusion between the plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication.
- Indication
For the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).
- Associated Conditions
- Cold Sore
Theralase's Light-Activated Ruvidar Shows Promising Results in BCG-Unresponsive Bladder Cancer Clinical Trial
• Theralase's Phase II clinical trial for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) shows 62.5% complete response rate with its light-activated small molecule Ruvidar.
• The therapy demonstrates impressive durability with 45% of complete responders maintaining cancer-free status for at least 12 months, and some patients showing responses lasting over 7 years.
• Theralase plans to complete trial enrollment by mid-2025, submit regulatory applications to Health Canada and FDA in late 2026, with potential market approval by early 2027.
Theralase's Ruvidar® Shows Complete Healing of HSV-1 Lesions in Preclinical Study
• Theralase's topical Ruvidar® treatment demonstrated complete healing of HSV-1 cutaneous lesions in mice after four days of application, marking a significant breakthrough in herpes treatment.
• The non-light activated therapy showed promising safety and efficacy in animal models, potentially offering new hope for billions affected by HSV infections worldwide.
• Researchers plan to advance the development of both a therapeutic treatment and preventive vaccine for HSV, with clinical trials to follow these successful preclinical results.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath